Observational studyBMC ophthalmology2026
Short-term real-world outcomes of switching to faricimab in anti-VEGF-refractory retinal vein occlusion: a prospective study.
Observational study in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Faricimab: current evidence for the treatment of retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.Ophthalmology and therapy · 2026Article
- Effectiveness and safety of intravitreal faricimab for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis.International journal of retina and vitreous · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate short-term real-world outcomes after switching to faricimab using a modified treat-and-extend (TAE) regimen with a single loading dose in patients with retinal vein occlusion (RVO) refractory to prior anti-VEGF therapy.
methodsIn this prospective study, 27 eyes of 27 patients with macular edema (ME) secondary to RVO and persistent intraretinal fluid (IRF) and central subfield thickness (CST) ≥ 270 μm despite ≥ 3 prior anti-VEGF injections at treatment intervals ≤ 6 weeks were switched to faricimab. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters, including CST, IRF, and subretinal fluid (SRF), were assessed from baseline (1st faricimab injection) until 3rd faricimab injection (final visit). Outcomes were analyzed for all RVO combined and stratified by central (CRVO) and branch retinal vein occlusion (BRVO).
resultsIn the all RVO combined cohort, median BCVA improved significantly from 0.2 logMAR to 0.1 logMAR (p = 0.022), and median CST decreased from 291 μm to 268 μm (p < 0.001) over a mean follow-up of 11.7 weeks. The proportion of eyes with IRF was significantly reduced (p < 0.001), and a dry macula was achieved in 48.1% of eyes at the final visit. The mean treatment interval increased significantly from 4.6 to 7.3 weeks, with an intended interval extension achieved in 88.9% of eyes. After stratification, both CRVO and BRVO subgroups showed significant CST reduction and significant treatment interval extension, while BCVA improved numerically in both subgroups without reaching statistical significance. No safety-related adverse events were observed.
conclusionsIn real-world practice, switching to faricimab using a modified TAE regimen with a single loading dose appears to be effective in RVO patients refractory to prior anti-VEGF therapy, yielding significant functional improvement with early interval extension and no safety concerns. CLINICAL TRIAL NUMBER: German Clinical Trials Register (DRKS) registration ID: DRKS00036984.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.